{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:40:13Z","timestamp":1793749213236,"version":"4.6.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Foundation BMS"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor (ICI)-induced (cardio)-myotoxicities, including myocarditis and myositis, are uncommon but frequently severe adverse drug reactions seen in cancer patients. Real-life ICI myotoxicity incidence estimates span from limited-size cohorts, with risk factors and prognosticators poorly established, as well as their impact on survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective French National Health Data System cohort study included all adult patients starting ICI between 1 January 2012 and 30 September 2022. A \u2018narrow\u2019 and a \u2018broad\u2019 code combination (based on International Classification of Diseases-10 codes) were used for studied outcomes. The primary outcome was the occurrence of myotoxicities and secondary outcomes of myocarditis and myositis. Risk factors of these outcomes at 6\u2005months were identified with Fine and Gray multivariable models, considering demographics, comorbidities, co-treatments, and cancer. Immune checkpoint inhibitor myotoxicity (as a time-dependent variable) association with overall survival was tested using Cox models. Risk factors of 1- and 3-month letality in ICI myotoxicity cases were assessed by multivariable logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 172 363 ICI-treated adult patients, incidence of ICI myotoxicities at 6\u2005months ranged between 0.7% and 0.9% (narrow or broad definitions, respectively), with up to 7.1% in patients with thymic cancer. Immune checkpoint inhibitor myocarditis and ICI myositis incidence ranged between 0.3% and 0.6%, co-occurring in \u223c13%\u201323% of cases. The main risk factors for developing ICI myotoxicities (broad, n = 1520) were thymic tumour (sub-distribution hazard ratio [sHR] 12.94, 95% confidence interval [CI] 5.22\u201332.03), melanoma (2.41 [2.06\u20132.83]) and other skin cancers (2.07 [1.55\u20132.76]), history of thymic disorders (5.61 [2.66\u201311.86]), history of myasthenia gravis (2.50 [1.45\u20134.32]), combination of ICI (2.44 [1.99\u20132.98]), and age &amp;gt; 85 [1.79 [1.24\u20132.59] vs &amp;lt;45\u2005years. Immune checkpoint inhibitor myotoxicity occurrence was the factor impacting most mortality after ICI start (HR 3.51 [95% CI 3.17\u20133.89] at 1\u2005month), over metastatic status (1.55 [1.52\u20131.58]). In ICI myotoxicity patients, 1-month fatality was 20.3% and increased if severe arrhythmia (risk ratio 1.64 [95% CI 1.03\u20132.61]), heart failure (1.49 [1.06\u20132.07]), and respiratory failure (1.50 [1.05\u20132.15]) were reported. Additionally, results were consistent with secondary outcomes, using narrow and broad definitions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This pharmaco-epidemiological study assessed &amp;gt;170 000 French patients treated by ICI in real life, establishing the incidence and identifying risk factors of developing ICI myotoxicities, with severity surrogates associated with fatality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf682","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:21:45Z","timestamp":1755516105000},"page":"1014-1030","source":"Crossref","is-referenced-by-count":31,"title":["Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-3307","authenticated-orcid":false,"given":"Joe-Elie","family":"Salem","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Department of Pharmacology, CIC-1901, AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re , 47 Boulevard de l\u2019Hopital, Paris 75013 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7615-9064","authenticated-orcid":false,"given":"Aya","family":"Ajrouche","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Equipe PEPITES , 47 Boulevard de l\u2019Hopital, Paris 75013 ,","place":["France"]},{"name":"INSERM, D\u00e9partement de Sant\u00e9 Publique, Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi), CIC-1901, AP-HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re , 47 Boulevard de l\u2019Hopital, Paris 75013 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Rozes","sequence":"additional","affiliation":[{"name":"INSERM, D\u00e9partement de Sant\u00e9 Publique, Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi), CIC-1901, AP-HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re , 47 Boulevard de l\u2019Hopital, Paris 75013 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Pinto","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Equipe PEPITES , 47 Boulevard de l\u2019Hopital, Paris 75013 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"De Rycke","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Equipe PEPITES , 47 Boulevard de l\u2019Hopital, Paris 75013 ,","place":["France"]},{"name":"INSERM, D\u00e9partement de Sant\u00e9 Publique, Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi), CIC-1901, AP-HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re , 47 Boulevard de l\u2019Hopital, Paris 75013 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7802-944X","authenticated-orcid":false,"given":"Florence","family":"Tubach","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Equipe PEPITES , 47 Boulevard de l\u2019Hopital, Paris 75013 ,","place":["France"]},{"name":"INSERM, D\u00e9partement de Sant\u00e9 Publique, Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi), CIC-1901, AP-HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re , 47 Boulevard de l\u2019Hopital, Paris 75013 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"2026030418565874800_ehaf682-B1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/annurev-pharmtox-022820-093805","article-title":"Clinical pharmacology and interplay of immune checkpoint agents: a Yin-Yang balance","volume":"61","author":"Geraud","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2026030418565874800_ehaf682-B2","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026030418565874800_ehaf682-B3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026030418565874800_ehaf682-B4","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026030418565874800_ehaf682-B5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41467-021-27631-8","article-title":"Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database","volume":"13","author":"Nguyen","year":"2022","journal-title":"Nat Commun"},{"key":"2026030418565874800_ehaf682-B6","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"2026030418565874800_ehaf682-B7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for alpha-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"2026030418565874800_ehaf682-B8","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"2026030418565874800_ehaf682-B9","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","article-title":"Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","volume":"29","author":"Fenioux","year":"2023","journal-title":"Nat Med"},{"key":"2026030418565874800_ehaf682-B10","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","volume":"47","author":"Power","year":"2026","journal-title":"Eur Heart J"},{"key":"2026030418565874800_ehaf682-B11","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026030418565874800_ehaf682-B12","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev d'\u00c9pid\u00e9miol Sant\u00e9 Publ"},{"key":"2026030418565874800_ehaf682-B13","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026030418565874800_ehaf682-B14","volume-title":"ANSM-CNAM E-P-GdisG","author":"Dufour","year":"2022"},{"key":"2026030418565874800_ehaf682-B15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10654-019-00494-6","article-title":"Principles of confounder selection","volume":"34","author":"VanderWeele","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"2026030418565874800_ehaf682-B16","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckz185.108","article-title":"The \u00abcartographie\u00bb tool (CNAM, France)","volume":"29","author":"Gastaldi-M\u00e9nager","year":"2019","journal-title":"Eur J Public Health"},{"key":"2026030418565874800_ehaf682-B17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/jvh.13788","article-title":"Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the French health insurance claims databases using the ANRS CO22 HEPATHER cohort","volume":"30","author":"Lam","year":"2023","journal-title":"J Viral Hepat"},{"key":"2026030418565874800_ehaf682-B18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jdv.16566","article-title":"Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database","volume":"35","author":"Grodner","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026030418565874800_ehaf682-B19","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1177\/0091270003258651","article-title":"Dose equivalency evaluation of Major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics","volume":"43","author":"Mager","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"2026030418565874800_ehaf682-B20","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026030418565874800_ehaf682-B21","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"key":"2026030418565874800_ehaf682-B22","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaccao.2022.11.004","article-title":"Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor-induced myocarditis","volume":"4","author":"Vasbinder","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026030418565874800_ehaf682-B23","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/ejhf.2265","article-title":"Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy","volume":"23","author":"Palaskas","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026030418565874800_ehaf682-B24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"2026030418565874800_ehaf682-B25","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026030418565874800_ehaf682-B26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"2026030418565874800_ehaf682-B27","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/sim.4780131007","article-title":"Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions","volume":"13","author":"Hess","year":"1994","journal-title":"Stat Med"},{"key":"2026030418565874800_ehaf682-B28","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","article-title":"Modeling survival data: extending the Cox model","author":"Therneau","year":"2000","journal-title":"Statistics for Biology and Health"},{"key":"2026030418565874800_ehaf682-B29","doi-asserted-by":"publisher","first-page":"101192","DOI":"10.1016\/j.lanepe.2024.101192","article-title":"Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study","volume":"50","author":"Plomp","year":"2025","journal-title":"Lancet Reg Health\u2014Europe"},{"key":"2026030418565874800_ehaf682-B30","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026030418565874800_ehaf682-B31","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0986"},{"key":"2026030418565874800_ehaf682-B32","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S0140-6736(18)31556-3","article-title":"Reporting of immune checkpoint inhibitor-associated myocarditis\u2014authors\u2019 reply","volume":"392","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"2026030418565874800_ehaf682-B33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-019-0535-y","article-title":"Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors","volume":"7","author":"Awadalla","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026030418565874800_ehaf682-B34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/cpt.3721","article-title":"Comedications associated with immune-related adverse events from immune-checkpoint inhibitors","volume":"118","author":"Laurent","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"2026030418565874800_ehaf682-B35","doi-asserted-by":"publisher","first-page":"573141","DOI":"10.3389\/fonc.2020.573141","article-title":"Significance of tumor mutation burden in immune infiltration and prognosis in cutaneous melanoma","volume":"10","author":"Kang","year":"2020","journal-title":"Front Oncol"},{"key":"2026030418565874800_ehaf682-B36","doi-asserted-by":"publisher","first-page":"1012016","DOI":"10.3389\/fimmu.2022.1012016","article-title":"Aging augments obesity-induced thymic involution and peripheral T cell exhaustion altering the \u201cobesity paradox\u201d","volume":"13","author":"Vick","year":"2023","journal-title":"Front Immunol"},{"key":"2026030418565874800_ehaf682-B37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"2026030418565874800_ehaf682-B38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios","volume":"21","author":"Hernan","year":"2010","journal-title":"Epidemiology"},{"key":"2026030418565874800_ehaf682-B39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-025-01250-9","article-title":"How hazard ratios can mislead and why it matters in practice","volume":"40","author":"Dumas","year":"2025","journal-title":"Eur J Epidemiol"},{"key":"2026030418565874800_ehaf682-B40","doi-asserted-by":"publisher","first-page":"i1981","DOI":"10.1136\/bmj.i1981","article-title":"Sparse data bias: a problem hiding in plain sight","volume":"352","author":"Greenland","year":"2016","journal-title":"BMJ"},{"key":"2026030418565874800_ehaf682-B41","doi-asserted-by":"publisher","first-page":"1080.1","DOI":"10.1136\/bmj.332.7549.1080","article-title":"The cost of dichotomising continuous variables","volume":"332","author":"Altman","year":"2006","journal-title":"BMJ"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/9\/1014\/64159335\/ehaf682.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/9\/1014\/64159335\/ehaf682.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T23:57:03Z","timestamp":1772668623000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/9\/1014\/8243743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,8,30]]},"published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf682","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,1]]},"published":{"date-parts":[[2025,8,30]]}}}